MDT-AP-2996
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 8.040000000000001
- os_event
- false
- age_years
- 6
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.969972423
- umap2_2d
- 4.098018526
- umap1_3d
- 2.930211452
- umap2_3d
- -2.078294843
- umap3_3d
- -2.221386801
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.440
- HEME_METABOLISM+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.130
- TNFA_SIGNALING_VIA_NFKB+0.110
- P53_PATHWAY+0.100
- PI3K_AKT_MTOR_SIGNALING+0.100
- MTORC1_SIGNALING+0.090
- FATTY_ACID_METABOLISM+0.080
- TGF_BETA_SIGNALING+0.080
- XENOBIOTIC_METABOLISM+0.080
Top 10 suppressed
- E2F_TARGETS-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- G2M_CHECKPOINT-0.390
- INTERFERON_ALPHA_RESPONSE-0.340
- ANGIOGENESIS-0.330
- ALLOGRAFT_REJECTION-0.310
- ESTROGEN_RESPONSE_LATE-0.270
- CHOLESTEROL_HOMEOSTASIS-0.250
- COAGULATION-0.240
- INTERFERON_GAMMA_RESPONSE-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3253 | Med | Medulloblastoma | 0.816 |
| 2 | BS_Z7PKVY9J | Med | Medulloblastoma | 0.816 |
| 3 | MDT-AP-3207 | Med | Medulloblastoma | 0.795 |
| 4 | BS_DFWFBYSN | Med | Medulloblastoma | 0.794 |
| 5 | MDT-AP-2744 | Med | Medulloblastoma | 0.776 |
| 6 | SRR12202451 | — | — | 0.776 |
| 7 | R357 | — | — | 0.776 |
| 8 | TCGA-D8-A1JN-01A-11R-A13Q-07 | — | C | 0.771 |
| 9 | SRR23303735 | — | — | 0.770 |
| 10 | MDT-AP-0566 | Med | Medulloblastoma | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| HYPOXIA | 0.030 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |